The Revlon Exemption: Why the Chancery Court’s Public Benefit Corporation Ruling Radically Alters Delaware M&A

The Prime Directive of Delaware M&A Just Got an Asterisk

For nearly forty years, the prime directive of Delaware corporate law has been etched in stone: when a board decides to sell the company or effect a change of control, the directors transition from defenders of the corporate bastion to auctioneers charged with securing the highest price for stockholders. That doctrine, born in Revlon, Inc. v. MacAndrews & Forbes Holdings, Inc., 506 A.2d 173 (Del. 1986), has been the bedrock of deal litigation and board advisement. But as of July 29, 2026, the Delaware Chancery Court has officially recognized a statutory escape hatch.

In a landmark decision, Judge Nathan Cook ruled that Public Benefit Corporations (PBCs) are not legally required to maximize sale price during a change of control. Instead, the court held that a PBC’s board must adhere to its statutory mandate to balance stockholder financial interests with the specific public-benefit purposes outlined in its charter, even at the expense of a higher monetary bid.

This ruling is a tectonic shift for corporate practitioners. It is not merely a victory for the ESG movement; it is the authorization of the ultimate defensive posture. For lawyers advising boards, founders, and activists, the Chancery Court just rewrote the M&A playbook, severely blunting the plaintiffs’ bar’s sharpest weapon in deal litigation.

Statutory Intent vs. Enhanced Scrutiny

To understand why this matters, you have to look at the collision between standard common-law fiduciary duties and Delaware’s relatively recent statutory experiment with PBCs. Under standard Delaware corporate law, a board's decision to sell the company triggers enhanced scrutiny under Revlon. The court will closely examine the board’s process to ensure its sole focus was maximizing shareholder value. Leaving money on the table in favor of a "better corporate fit" is a fast track to an injunction or personal liability.

However, Del. Code Ann. tit. 8, § 365 mandates that directors of a PBC balance three factors: (1) the pecuniary interests of the stockholders, (2) the best interests of those materially affected by the corporation’s conduct, and (3) the specific public benefit identified in its certificate of incorporation.

"The statutory mandate of a Public Benefit Corporation fundamentally alters the fiduciary landscape," Judge Cook’s logic dictates. "To impose a strict Revlon duty of price maximization would require directors to violate their affirmative statutory obligation to weigh non-pecuniary stakeholder interests."

By ruling that the Subchapter XV balancing requirement overrides Revlon duties in a sale context, the Chancery Court has effectively immunized PBC boards from traditional price-maximization claims, provided the board can demonstrate it engaged in a good-faith balancing exercise.

The Double-Edged Sword of the "Mission-Fit" Defense

Let’s be direct about what this means in practice: this ruling creates a massive, legally sanctioned loophole for entrenchment and deal favoritism, cloaked in the noble language of public benefit.

Imagine a scenario where a PBC receives two competing buyout offers. Bidder A, a ruthless private equity firm, offers $50 per share but plans to gut the company's environmentally friendly supply chain. Bidder B, a mission-aligned competitor, offers $40 per share and promises to maintain the company's sustainability initiatives. Under traditional Revlon, the board would almost certainly be forced to take the $50 bid or face intense litigation risk. Post-July 29, the PBC board can confidently reject the premium bid, citing its statutory duty to protect its environmental mandate.

While this empowers founders to protect their life’s work from corporate raiders, it also provides a convenient shield for boards to reject hostile bids that threaten their own positions, simply by pointing to a "misalignment of public benefit." The business judgment rule, which protects a PBC board’s balancing decision under § 365(b) so long as it is informed and disinterested, is a notoriously difficult standard for plaintiffs to overcome.

Practical Takeaways for Dealmakers and Litigators

This ruling alters the daily reality of corporate transactions in several immediate ways:

• The Pre-IPO PBC Conversion Surge: Expect corporate counsel to aggressively push PBC conversions for startups before they go public. The ability to structurally opt out of Revlon makes the PBC form incredibly attractive to founders who want to retain control over the company’s ultimate exit, free from the absolute tyranny of short-term price maximization.
• Auction Process Redesign: M&A advisors and bankers selling a PBC must fundamentally restructure their auction processes. A traditional price-driven auction is no longer legally required or appropriate. Deal processes will need to explicitly incorporate "mission-fit" diligence, where bidders submit proposals on how they intend to uphold the target’s specific public benefits post-closing.
• Deal Litigation Pivots: The plaintiffs' bar can no longer rely on the standard "failure to maximize value" playbook when challenging a PBC sale. Instead, litigation will hinge on whether the board’s balancing process was a sham. Plaintiffs will have to dig into board minutes and banker books to prove that the directors acted in bad faith or had undisclosed conflicts of interest when they claimed to be protecting the corporate mission.
• Drafting Merger Agreements: Buyers acquiring a PBC will face intense negotiation over post-closing covenants. Target boards, needing to justify their balancing act to stockholders, will demand binding commitments from the buyer to maintain the public benefit, creating complex enforcement issues post-integration.

The Delaware Chancery Court has finally answered the most pressing theoretical question regarding Public Benefit Corporations. The answer—that Revlon does not apply—transforms the PBC from a niche ESG marketing tool into one of the most potent defensive structures in modern corporate governance. For practicing M&A lawyers, the era of absolute price maximization has officially fractured.